Usefulness of kestose with Inflammatory Bowel Disease

Usefulness of kestose with Inflammatory Bowel Disease - Treatment with kestose for Inflammatory Bowel Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028203

Enrollment

Registered

2017-07-12

Start date

2018-04-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease

Interventions

kestose placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed as Inflammatory Bowel Disease(ulcerative colitis,crohn disease)

Exclusion criteria

Exclusion criteria: 1.Women with pregnancy or possible pregnancy 2.Patients with severe renal failure and heart failure 3.Patient who is considered to be inappropriate for entry into the trial by the investigator 4.Medical doctors decided the patients are inappropriate.

Design outcomes

Primary

Measure	Time frame
Improvement of clinical condition in patients with Inflammatory Bowel Disease	—

Secondary

Measure	Time frame
1.Changes of short-chain fatty acid (Butyric acid,Acetic acid,Propionic acid etc.) 2.changes of endoscopic score 3.changes of concentration of carprotectin in feces 4.Changes of pathologic and metabolic marker (T.Cho, LDL-Cho, HDL-Cho, TG, FFA, ferritin,HbA1c,CRP,TP,ALB etc.) 5.Correlation of gut microbiota and therapeutic effect 6.Changes of body weight and BMI 7.Metabolome and protein analysis of metabolite in feces 8.Changes of bile acid 9.Correlation between expiratory noble gases, gut microbiota and NAFLD/NASH 10.Correlation between usefulness of kestose and disease prognosis in the patients with Inflammatory Bowel Disease	—

Measure

Time frame

1.Changes of short-chain fatty acid (Butyric acid,Acetic acid,Propionic acid etc.) 2.changes of endoscopic score 3.changes of concentration of carprotectin in feces 4.Changes of pathologic and metabolic marker (T.Cho, LDL-Cho, HDL-Cho, TG, FFA, ferritin,HbA1c,CRP,TP,ALB etc.) 5.Correlation of gut microbiota and therapeutic effect 6.Changes of body weight and BMI 7.Metabolome and protein analysis of metabolite in feces 8.Changes of bile acid 9.Correlation between expiratory noble gases, gut microbiota and NAFLD/NASH 10.Correlation between usefulness of kestose and disease prognosis in the patients with Inflammatory Bowel Disease

—

Countries

Japan

Contacts

Public ContactKeisaku yamada

Nagoya University Hospital Department of Gastroenterology and Hepatology

kei-yama@med.nagoya-u.ac.jp+81-52-744-2602

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026